Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

With TORNTPHARM's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.000000
forwardPE 42.903965
debtToEquity 41.658000
earningsGrowth 0.136000
revenueGrowth 0.028000
grossMargins 0.758960
operatingMargins 0.254540
trailingEps 54.950000
forwardEps 0.000000

Torrent Pharmaceuticals Limited's positive gross and operating margins reflect its profitability and efficiency. These metrics demonstrate the company's ability to manage costs effectively while generating strong revenue, highlighting its solid financial health and operational effectiveness.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

Over time, analysts have gradually revised TORNTPHARM's price projections downward. This suggests growing concerns about the company's ability to meet previous expectations, pointing to a more conservative outlook.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


1 separate transactions to buy TORNTPHARM were completed, while market price hovered around 3224.449951171875.No buy transactions were carried out during the period under review.TORNTPHARM's current price levels are marked by more sells than buys, potentially signaling a price decline. If this trend continues, it may suggest that investors expect the stock to drop further in value.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


Analysts have shown a buy bias for Torrent Pharmaceuticals Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Torrent Pharmaceuticals Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.